• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

7 New Drugs Approved for Primary Care: Q1 2022

Slideshow

At the close of the first quarter of a new year, Patient Care Online has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on a new oral solution of amlodipine; the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of attention deficit hyperactivity disorder; and 5 more.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone

Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone

April 22nd 2024
Article

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose

April 19th 2024
Article

Your daily dose of the clinical news you may have missed.

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

October 25th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma / Image credit: ©Argus/AdobeStock

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma

April 11th 2024
Article

The additional indication for benralizumab was supported by data from the phase 3 TATE trial.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research / image credit older man in hospital ©auremar/stock.adobe.com

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research

April 11th 2024
Article

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

© 2024 MJH Life Sciences

All rights reserved.